DOCSLIB.ORG

LRP1 Controls TNF Release Via the TIMP-3/ADAM17 Axis in Endotoxin-Activated Macrophages

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LRP1 Controls TNF Release Via the TIMP-3/ADAM17 Axis in Endotoxin-Activated Macrophages LRP1 Controls TNF Release via the TIMP-3/ADAM17 Axis in Endotoxin-Activated Macrophages This information is current as Kristin Schubert, Laura E. Collins, Patricia Green, Hideaki of September 25, 2021. Nagase and Linda Troeberg J Immunol published online 18 January 2019 http://www.jimmunol.org/content/early/2019/01/17/jimmun ol.1800834 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2019/01/17/jimmunol.180083 Material 4.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published January 18, 2019, doi:10.4049/jimmunol.1800834 The Journal of Immunology LRP1 Controls TNF Release via the TIMP-3/ADAM17 Axis in Endotoxin-Activated Macrophages Kristin Schubert,1 Laura E. Collins, Patricia Green, Hideaki Nagase, and Linda Troeberg The metalloproteinase ADAM17 plays a pivotal role in initiating inflammation by releasing TNF from its precursor. Prolonged TNF release causes many chronic inflammatory diseases, indicating that tight regulation of ADAM17 activity is essential for resolution of inflammation. In this study, we report that the endogenous ADAM17 inhibitor TIMP-3 inhibits ADAM17 activity only when it is bound to the cell surface and that cell surface levels of TIMP-3 in endotoxin-activated human macrophages are dynamically con- trolled by the endocytic receptor LRP1. Pharmacological blockade of LRP1 inhibited endocytic clearance of TIMP-3, leading to an increase in cell surface levels of the inhibitor that blocked TNF release. Following LPS stimulation, TIMP-3 levels on the surface of macrophages increased 4-fold within 4 h and continued to accumulate at 6 h, before a return to baseline levels at 8 h. This dynamic Downloaded from regulation of cell surface TIMP-3 levels was independent of changes in TIMP-3 mRNA levels, but correlated with shedding of LRP1. These results shed light on the basic mechanisms that maintain a regulated inflammatory response and ensure its timely resolution. The Journal of Immunology, 2019, 202: 000–000. disintegrin and metalloproteinase 17 (ADAM17) reg- by substrate availability, either by localization (7), dimerization ulates paracrine and autocrine immune signaling, cell (18), intracellular domain phosphorylation (19), or glycosylation http://www.jimmunol.org/ A proliferation, tissue regeneration, and cancer progression (20). Regulation of ADAM17 intracellular trafficking by iRhoms through its ability to cleave or “shed” the transmembrane pre- (21–23) and the sorting protein PACS2 (24) also contribute to cursors of multiple cytokine and growth factor proteins and re- the interrelated network of molecular mechanisms regulating ceptors. Key ADAM17 substrates include the precursor form of ADAM17 activation. the inflammatory cytokine TNF, giving the enzyme its alternative Prolonged or increased TNF release is associated with numerous name of TNF-a–converting enzyme (TACE) (1–4). Although the inflammatory conditions, such as septic shock (25), rheumatoid transmembrane TNF precursor has biological activity, in vivo arthritis (26), colitis (27, 28), and Crohn’s disease (29), indicating studies indicate that the soluble form of the cytokine plays in- that ADAM17 activity must be tightly regulated. Although acti- by guest on September 25, 2021 dispensable roles in initiating paracrine signaling events central to vation of ADAM17 has been studied in detail, mechanisms con- acute inflammatory responses (5, 6). trolling resolution of ADAM17 activity are less well understood. ADAM17 activity is rapidly induced in response to LPS or PMA Tissue inhibitor of metalloproteinases 3 (TIMP-3) inhibits ADAM17 stimulation, without any increase in its cell surface expression. activity by forming a high affinity 1:1 stoichiometric complex with the Many mechanisms have been proposed to explain this phenome- enzyme (30). Timp3-null mice exhibit increased TNF release (5, 31– non, including compartmentalization of the enzyme in membrane 33) and increased susceptibility to TNF-associated tissue damage in microdomains (7, 8) and conformational changes in the ADAM17 models of diabetes (31), atherosclerosis (34), kidney fibrosis (33), lung ectodomain (9, 10), postulated to involve protein disulfide isom- injury (35) and liver regeneration (5). These studies indicate that erase (10, 11) and/or interaction of juxtamembrane regions of TIMP-3 is the primary physiological inhibitor of ADAM17 and that ADAM17 with the lipid bilayer (12). Phosphorylation of the in- TIMP-3 is critical for termination of TNF release. tracellular domain of ADAM17 affects activity in some cases We have previously demonstrated that extracellular levels of (13–17), but not all (9). ADAM17 activity may also be regulated TIMP-3 in chondrocytes are primarily regulated posttranslationally, by endocytosis via the endocytic scavenger receptor low-density Arthritis Research UK Centre for Osteoarthritis Pathogenesis, Kennedy Institute of lipoprotein receptor-related protein 1 (LRP1) and subsequent deg- Rheumatology, University of Oxford, Oxford OX3 7FY, United Kingdom radation in lysosomes (36–38). Because LRP1 is also highly 1 Current address: Department for Molecular Systems Biology, Helmholtz Centre for expressed in macrophages (39, 40), we investigated whether LRP1 Environmental Research UFZ, Leipzig, Germany. also controls TIMP-3 levels in these cells and whether LRP1 has an ORCIDs: 0000-0003-4365-084X (K.S.); 0000-0003-0939-4651 (L.T.). impact on the duration of ADAM17 activity and TNF release. By Received for publication June 14, 2018. Accepted for publication December 16, 2018. studying primary human macrophages stimulated with LPS, we were able to gain insight into physiological TIMP-3 and ADAM17 This work was supported by the Kennedy Trust for Rheumatology Research. regulation that has not been observed in previous studies using Address correspondence and reprint requests to Dr. Linda Troeberg at the current address: Norwich Medical School, Bob Champion Research and Education Building, macrophage-like cell lines (e.g., THP-1 or U937) or nonphysiological University of East Anglia, Norwich NR4 7UQ, U.K. E-mail address: [email protected] stimuli (e.g., PMA). We found that LPS-induced shedding of LRP1 The online version of this article contains supplemental material. from activated macrophages led to an accumulation of TIMP-3 on Abbreviations used in this article: ADAM17, a disintegrin and metalloproteinase 17; the cell surface, and consequent inhibition of TNF release. LRP1 HSPG, heparan sulfate proteoglycan; LRP1, low-density lipoprotein receptor-related pro- thus controls the duration of ADAM17 activity by regulating the tein 1; RAP, receptor-associated protein; TIMP-3, tissue inhibitor of metalloproteinases 3. abundance of its inhibitor, and contributes to the regulated resolution Copyright Ó 2019 by The American Association of Immunologists, Inc. 0022-1767/19/$37.50 of inflammation. www.jimmunol.org/cgi/doi/10.4049/jimmunol.1800834 2 LRP1 REGULATES MACROPHAGE TNF RELEASE Materials and Methods Change in TNF concentration per hour Materials ½TNF concentration at x 2 ½TNF concentration at y ¼ ; FCS was from Life Technologies, RPMI 1640 medium was from PAA x 2 y Laboratories, and recombinant human GM-CSF, M-CSF, and IL-4 were where x and y represent successive time points. from PeproTech. Ultra-pure LPS from Escherichia coli 0111:B4 was from InvivoGen. Recombinant human TIMP-3, TIMP-3 blocking Ab (catalog Flow cytometry number MAB973, clone number 183551), and IL-6R ELISA kit were from R&D Systems. For immunoblotting, the TIMP-3 Ab (AB6000) was from Macrophages were detached by incubating in 2 mM EDTA/PBS for 10 min Merck Millipore, and the actin Ab (ab3280) was from Abcam. LRP1 at 37˚C. Fc receptors were blocked using 10% human AB serum. Cells blocking Ab (01-05) was purchased from BioMac. Porcine mucosal hep- were stained with fixable viability dye (eBioscience), conjugated Abs arin, PMA, and ionomycin were from Sigma-Aldrich (St Louis, MO). against ADAM17 (FAB9301F; R&D Systems), LRP-1 a-chain (12-0919- Receptor-associated protein (RAP) was expressed in E. coli and purified as 42; eBioscience), LRP1 b-chain (FAB6360A; R&D Systems), membrane *previously described (41), with addition of a Triton X-114 washing step TNF (HM2024F; Hycult Biotech), or matching isotope controls for 30 min to remove LPS (42). Removal of LPS was confirmed by the Limulus at 4˚C, washed, and fixed. The Ab against the LRP1 b-chain recognizes the Amebocyte Lysate assay (Pierce). intracellular portion of the b-chain, and cells were thus permeabilized using the Cytofix/Cytoperm Kit (BD Bioscience) according to manufacturer’s in- Cell isolation and culture structions. Samples were then analyzed on an LSR II (BD Bioscience),
Load more

Recommended publications
  • LRP1 Shedding in Human Brain: Roles of ADAM10 and ADAM17 Qiang Liu Washington University School of Medicine in St
    Washington University School of Medicine Digital Commons@Becker ICTS Faculty Publications Institute of Clinical and Translational Sciences 2009 LRP1 shedding in human brain: roles of ADAM10 and ADAM17 Qiang Liu Washington University School of Medicine in St. Louis Juan Zhang Washington University School of Medicine in St. Louis Hien Tran Washington University School of Medicine in St. Louis Marcel M. Verbeek Radboud University Nijmegen Medical Centre Karina Reiss Christian-Albrecht University Kiel See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/icts_facpubs Part of the Medicine and Health Sciences Commons Recommended Citation Liu, Qiang; Zhang, Juan; Tran, Hien; Verbeek, Marcel M.; Reiss, Karina; Estus, Steven; and Bu, Guojun, "LRP1 shedding in human brain: roles of ADAM10 and ADAM17". Molecular Neurodegeneration, 17. 2009. Paper 85. https://digitalcommons.wustl.edu/icts_facpubs/85 This Article is brought to you for free and open access by the Institute of Clinical and Translational Sciences at Digital Commons@Becker. It has been accepted for inclusion in ICTS Faculty Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Authors Qiang Liu, Juan Zhang, Hien Tran, Marcel M. Verbeek, Karina Reiss, Steven Estus, and Guojun Bu This article is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/icts_facpubs/85 Molecular Neurodegeneration BioMed Central Research article Open Access LRP1 shedding
    [Show full text]
  • Management of Brain and Leptomeningeal Metastases from Breast Cancer
    International Journal of Molecular Sciences Review Management of Brain and Leptomeningeal Metastases from Breast Cancer Alessia Pellerino 1,* , Valeria Internò 2 , Francesca Mo 1, Federica Franchino 1, Riccardo Soffietti 1 and Roberta Rudà 1,3 1 Department of Neuro-Oncology, University and City of Health and Science Hospital, 10126 Turin, Italy; [email protected] (F.M.); [email protected] (F.F.); riccardo.soffi[email protected] (R.S.); [email protected] (R.R.) 2 Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, 70121 Bari, Italy; [email protected] 3 Department of Neurology, Castelfranco Veneto and Treviso Hospital, 31100 Treviso, Italy * Correspondence: [email protected]; Tel.: +39-011-6334904 Received: 11 September 2020; Accepted: 10 November 2020; Published: 12 November 2020 Abstract: The management of breast cancer (BC) has rapidly evolved in the last 20 years. The improvement of systemic therapy allows a remarkable control of extracranial disease. However, brain (BM) and leptomeningeal metastases (LM) are frequent complications of advanced BC and represent a challenging issue for clinicians. Some prognostic scales designed for metastatic BC have been employed to select fit patients for adequate therapy and enrollment in clinical trials. Different systemic drugs, such as targeted therapies with either monoclonal antibodies or small tyrosine kinase molecules, or modified chemotherapeutic agents are under investigation. Major aims are to improve the penetration of active drugs through the blood–brain barrier (BBB) or brain–tumor barrier (BTB), and establish the best sequence and timing of radiotherapy and systemic therapy to avoid neurocognitive impairment. Moreover, pharmacologic prevention is a new concept driven by the efficacy of targeted agents on macrometastases from specific molecular subgroups.
    [Show full text]
  • The Diverse Roles of TIMP-3: Insights Into Degenerative Diseases of the Senescent Retina and Brain
    cells Review The Diverse Roles of TIMP-3: Insights into Degenerative Diseases of the Senescent Retina and Brain Jennifer M. Dewing 1, Roxana O. Carare 1, Andrew J. Lotery 1,2 and J. Arjuna Ratnayaka 1,* 1 Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, MP806, Tremona Road, Southampton SO16 6YD, UK; [email protected] (J.M.D.); [email protected] (R.O.C.); [email protected] (A.J.L.) 2 Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK * Correspondence: [email protected]; Tel.: +44-238120-8183 Received: 13 November 2019; Accepted: 19 December 2019; Published: 21 December 2019 Abstract: Tissue inhibitor of metalloproteinase-3 (TIMP-3) is a component of the extracellular environment, where it mediates diverse processes including matrix regulation/turnover, inflammation and angiogenesis. Rare TIMP-3 risk alleles and mutations are directly linked with retinopathies such as age-related macular degeneration (AMD) and Sorsby fundus dystrophy, and potentially, through indirect mechanisms, with Alzheimer’s disease. Insights into TIMP-3 activities may be gleaned from studying Sorsby-linked mutations. However, recent findings do not fully support the prevailing hypothesis that a gain of function through the dimerisation of mutated TIMP-3 is responsible for retinopathy. Findings from Alzheimer’s patients suggest a hitherto poorly studied relationship between TIMP-3 and the Alzheimer’s-linked amyloid-beta (Aβ) proteins that warrant further scrutiny. This may also have implications for understanding AMD as aged/diseased retinae contain high levels of Aβ. Findings from TIMP-3 knockout and mutant knock-in mice have not led to new treatments, particularly as the latter does not satisfactorily recapitulate the Sorsby phenotype.
    [Show full text]
  • Endothelial LRP1 Transports Amyloid-Β1–42 Across the Blood- Brain Barrier
    Endothelial LRP1 transports amyloid-β1–42 across the blood- brain barrier Steffen E. Storck, … , Thomas A. Bayer, Claus U. Pietrzik J Clin Invest. 2016;126(1):123-136. https://doi.org/10.1172/JCI81108. Research Article Neuroscience According to the neurovascular hypothesis, impairment of low-density lipoprotein receptor–related protein-1 (LRP1) in brain capillaries of the blood-brain barrier (BBB) contributes to neurotoxic amyloid-β (Aβ) brain accumulation and drives Alzheimer’s disease (AD) pathology. However, due to conflicting reports on the involvement of LRP1 in Aβ transport and the expression of LRP1 in brain endothelium, the role of LRP1 at the BBB is uncertain. As global Lrp1 deletion in mice is lethal, appropriate models to study the function of LRP1 are lacking. Moreover, the relevance of systemic Aβ clearance to AD pathology remains unclear, as no BBB-specific knockout models have been available. Here, we developed transgenic mouse strains that allow for tamoxifen-inducible deletion of Lrp1 specifically within brain endothelial cells (Slco1c1- CreERT2 Lrp1fl/fl mice) and used these mice to accurately evaluate LRP1-mediated Aβ BBB clearance in vivo. Selective 125 deletion of Lrp1 in the brain endothelium of C57BL/6 mice strongly reduced brain efflux of injected [ I] Aβ1–42. Additionally, in the 5xFAD mouse model of AD, brain endothelial–specific Lrp1 deletion reduced plasma Aβ levels and elevated soluble brain Aβ, leading to aggravated spatial learning and memory deficits, thus emphasizing the importance of systemic Aβ elimination via the BBB. Together, our results suggest that receptor-mediated Aβ BBB clearance may be a potential target for treatment and prevention of Aβ brain accumulation in AD.
    [Show full text]
  • Over-Expression of Low-Density Lipoprotein Receptor-Related Protein-1 Is Associated with Poor Prognosis and Invasion in Pancreatic Ductal Adenocarcinoma
    Pancreatology 19 (2019) 429e435 Contents lists available at ScienceDirect Pancreatology journal homepage: www.elsevier.com/locate/pan Over-expression of low-density lipoprotein receptor-related Protein-1 is associated with poor prognosis and invasion in pancreatic ductal adenocarcinoma Ali Gheysarzadeh a, Amir Ansari a, Mohammad Hassan Emami b, * Amirnader Emami Razavi c, Mohammad Reza Mofid a, a Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran b Gastrointestinal and Hepatobiliary Diseases Research Center, Poursina Hakim Research Institute for Health Care Development, Isfahan, Iran c Iran National Tumor Bank, Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran article info abstract Article history: Background: Low-density lipoprotein receptor-Related Protein-1 (LRP-1) has been reported to involve in Received 1 December 2018 tumor development. However, its role in pancreatic cancer has not been elucidated. The present study Received in revised form was designed to evaluate the expression of LRP-1 in Pancreatic Ductal Adenocarcinoma Cancer (PDAC) as 16 February 2019 well as its association with prognosis. Accepted 23 February 2019 Methods: Here, 478 pancreatic cancers were screened for suitable primary PDAC tumors. The samples Available online 14 March 2019 were analyzed using qRT-PCR, western blotting, and Immunohistochemistry (IHC) staining as well as LRP-1 expression in association with clinicopathological features. Keywords: PDAC Results: The relative LRP-1 mRNA expression was up-regulated in 82.3% (42/51) of the PDAC tumors and ± fi ± LRP-1 its expression (3.72 1.25) was signi cantly higher than that in pancreatic normal margins (1.0 0.23, Prognosis P < 0.05).
    [Show full text]
  • Suramin Inhibits Osteoarthritic Cartilage Degradation by Increasing Extracellular Levels
    Molecular Pharmacology Fast Forward. Published on August 10, 2017 as DOI: 10.1124/mol.117.109397 This article has not been copyedited and formatted. The final version may differ from this version. MOL #109397 Suramin inhibits osteoarthritic cartilage degradation by increasing extracellular levels of chondroprotective tissue inhibitor of metalloproteinases 3 (TIMP-3). Anastasios Chanalaris, Christine Doherty, Brian D. Marsden, Gabriel Bambridge, Stephen P. Wren, Hideaki Nagase, Linda Troeberg Arthritis Research UK Centre for Osteoarthritis Pathogenesis, Kennedy Institute of Downloaded from Rheumatology, University of Oxford, Roosevelt Drive, Headington, Oxford OX3 7FY, UK (A.C., C.D., G.B., H.N., L.T.); Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford, Oxford, OX3 7FZ, UK (S.P.W.); Structural Genomics Consortium, molpharm.aspetjournals.org University of Oxford, Old Road Campus Research Building, Old Road Campus, Roosevelt Drive, Headington, Oxford, OX3 7DQ (BDM). at ASPET Journals on September 29, 2021 1 Molecular Pharmacology Fast Forward. Published on August 10, 2017 as DOI: 10.1124/mol.117.109397 This article has not been copyedited and formatted. The final version may differ from this version. MOL #109397 Running title: Repurposing suramin to inhibit osteoarthritic cartilage loss. Corresponding author: Linda Troeberg Address: Kennedy Institute of Rheumatology, University of Oxford, Roosevelt Drive, Headington, Oxford OX3 7FY, UK Phone number: +44 (0)1865 612600 E-mail: [email protected] Downloaded
    [Show full text]
  • Lrp1 Modulators
    Last updated on February 14, 2021 Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Lrp1 Modulators Evidence Summary Lrp1 has a variety of essential functions, mediated by a diverse array of ligands. Therapeutics will need to target specific interactions. Neuroprotective Benefit: Lrp1-mediated interactions promote Aβ clearance, Aβ generation, tau propagation, brain glucose utilization, and brain lipid homeostasis. The therapeutic effect will depend on the interaction targeted. Aging and related health concerns: Lrp1 plays mixed roles in cardiovascular diseases and cancer, dependent on context. Lrp1 is dysregulated in metabolic disease, which may contribute to insulin resistance. Safety: Broad-spectrum Lrp1 modulators are untenable therapeutics due to the high potential for extensive side effects. Therapies that target a specific Lrp1-ligand interaction are expected to have a better therapeutic profile. 1 Last updated on February 14, 2021 Availability: Research use Dose: N/A Chemical formula: N/A S16 is in clinical trials MW: N/A Half life: N/A BBB: Angiopep is a peptide that facilitates BBB penetrance by interacting with Lrp1 Clinical trials: S16, an Lrp1 Observational studies: sLrp1 levels are agonist was tested in healthy altered in Alzheimer’s disease, volunteers (n=10) in a Phase 1 cardiovascular disease, and metabolic study.
    [Show full text]
  • LRP1 Influences Trafficking of N-Type Calcium Channels Via Interaction
    www.nature.com/scientificreports OPEN LRP1 influences trafficking of N-type calcium channels via interaction with the auxiliary α2δ-1 Received: 17 November 2016 Accepted: 30 January 2017 subunit Published: 03 March 2017 Ivan Kadurin, Simon W. Rothwell, Beatrice Lana, Manuela Nieto-Rostro & Annette C. Dolphin 2+ Voltage-gated Ca (CaV) channels consist of a pore-forming α1 subunit, which determines the main functional and pharmacological attributes of the channel. The CaV1 and CaV2 channels are associated with auxiliary β- and α2δ-subunits. The molecular mechanisms involved in α2δ subunit trafficking, and the effect ofα 2δ subunits on trafficking calcium channel complexes remain poorly understood. Here we show that α2δ-1 is a ligand for the Low Density Lipoprotein (LDL) Receptor-related Protein-1 (LRP1), a multifunctional receptor which mediates trafficking of cargoes. This interaction with LRP1 is direct, and is modulated by the LRP chaperone, Receptor-Associated Protein (RAP). LRP1 regulates α2δ binding to gabapentin, and influences calcium channel trafficking and function. Whereas LRP1 alone reducesα 2δ-1 trafficking to the cell-surface, the LRP1/RAP combination enhances mature glycosylation, proteolytic processing and cell-surface expression of α2δ-1, and also increase plasma-membrane expression and function of CaV2.2 when co-expressed with α2δ-1. Furthermore RAP alone produced a small increase in cell-surface expression of CaV2.2, α2δ-1 and the associated calcium currents. It is likely to be interacting with an endogenous member of the LDL receptor family to have these effects. Our findings now provide a key insight and new tools to investigate the trafficking of calcium channelα 2δ subunits.
    [Show full text]
  • Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches
    cancers Review Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches Alessia Pellerino 1,* , Priscilla K. Brastianos 2, Roberta Rudà 1,3 and Riccardo Soffietti 1 1 Department of Neuro-Oncology, University and City of Health and Science Hospital, 10126 Turin, Italy; [email protected] (R.R.); riccardo.soffi[email protected] (R.S.) 2 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02115, USA; [email protected] 3 Department of Neurology, Castelfranco Veneto and Brain Tumor Board Treviso Hospital, 31100 Treviso, Italy * Correspondence: [email protected]; Tel.: +39-011-633-4904 Simple Summary: Leptomeningeal metastases are a devastating complication of solid tumors with poor survival, regardless of the type of treatments. The limited efficacy of targeted agents is due to the molecular divergence between leptomeningeal recurrences and primary site, as well as the presence of a heterogeneous blood-brain barrier and blood-tumor barrier that interfere with the penetration of drugs into the brain. The diagnosis of leptomeningeal metastases is achieved by neurological examination, and/or brain and spinal magnetic resonance, and/or a positive cerebrospinal fluid cytology. The presence of neoplastic cells in the cerebrospinal fluid examination is the gold-standard for the diagnosis of leptomeningeal metastases; however, novel techniques known as “liquid biopsy” aim to improve the sensitivity and specificity in detecting circulating neoplastic cells or DNA in the cerebrospinal fluid. Targeted therapies and immunotherapies have changed the natural history Citation: Pellerino, A.; Brastianos, of metastatic solid tumors, including lung, breast cancer, and melanoma. Targeting actionable P.K.; Rudà, R.; Soffietti, R.
    [Show full text]
  • Activated Α2-Macroglobulin Regulates LRP1 Levels at the Plasma
    www.nature.com/scientificreports OPEN Activated α2-Macroglobulin Regulates LRP1 Levels at the Plasma Membrane through the Received: 3 May 2019 Accepted: 19 August 2019 Activation of a Rab10-dependent Published: xx xx xxxx Exocytic Pathway in Retinal Müller Glial Cells Javier R. Jaldín-Fincati 1,2,3, Virginia Actis Dato1,2, Nicolás M. Díaz1,2, María C. Sánchez1,2, Pablo F. Barcelona1,2 & Gustavo A. Chiabrando 1,2 Activated α2-macroglobulin (α2M*) and its receptor, low-density lipoprotein receptor-related protein 1 (LRP1), have been linked to proliferative retinal diseases. In Müller glial cells (MGCs), the α2M*/LRP1 interaction induces cell signaling, cell migration, and extracellular matrix remodeling, processes closely associated with proliferative disorders. However, the mechanism whereby α2M* and LRP1 participate in the aforementioned pathologies remains incompletely elucidated. Here, we investigate whether α2M* regulates both the intracellular distribution and sorting of LRP1 to the plasma membrane (PM) and how this regulation is involved in the cell migration of MGCs. Using a human Müller glial-derived cell line, MIO-M1, we demonstrate that the α2M*/LRP1 complex is internalized and rapidly reaches early endosomes. Afterward, α2M* is routed to degradative compartments, while LRP1 is accumulated at the PM through a Rab10-dependent exocytic pathway regulated by PI3K/Akt. Interestingly, Rab10 knockdown reduces both LRP1 accumulation at the PM and cell migration of MIO-M1 cells induced by α2M*. Given the importance of MGCs in the maintenance of retinal homeostasis, unravelling this molecular mechanism can potentially provide new therapeutic targets for the treatment of proliferative retinopathies. Te low-density lipoprotein (LDL) receptor-related protein 1 (LRP1) is a member of the LDL receptor gene family.
    [Show full text]
  • Prognostic Significance of TIMP-1 in Non-Small Cell Lung Cancer
    ANTICANCER RESEARCH 31: 4031-4038 (2011) Prognostic Significance of TIMP-1 in Non-small Cell Lung Cancer MARTIN PESTA1, VLASTIMIL KULDA2, RADEK KUCERA1, MILOS PESEK3, JINDRA VRZALOVA1, VACLAV LISKA4, LADISLAV PECEN1, VLADISLAV TRESKA4, JARMIL SAFRANEK4, MARKETA PRAZAKOVA1, ONDREJ VYCITAL4, JAN BRUHA4, LUBOS HOLUBEC5 and ONDREJ TOPOLCAN1 Departments of 1Internal Medicine II and 2Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Czech Republic; 3TRN Clinic, University Hospital and Medical Faculty in Pilsen, Czech Republic; Departments of 4Surgery and 5Oncology, University Teaching Hospital, Pilsen, Czech Republic Abstract. Tissue inhibitor of metalloproteinases 1 (TIMP1) the mortality 48.7/100 000 per year (1). Non-small cell lung regulates not only extracellular matrix catabolism but the cancer (NSCLC) accounts for 80% of all cases (2). major effect in tumor tissue is promotion of cell growth and Although there are tumor markers routinely used for solid anti-apoptotic activity. The aim of our study was to evaluate tumors, some of them having become gold standards (3), plasma TIMP1 levels and tissue TIMP1 mRNA expression as there is still an effort being made to search for new ones. prognostic markers in NSCLC patients. Patients and Tissue inhibitor of metalloproteinases 1 (TIMP1) has been Methods: We studied a group of 108 patients with NSCLC studied intensively over the last ten years and in colorectal who had undergone lung surgery. Estimation of TIMP1 cancer it seems to be promising as a prognostic marker in mRNA was performed by quantitative polymerase chain clinical use (4). A Danish-Australian endoscopy study group reaction (qPCR) and estimation of plasma TIMP1 protein on colorectal cancer detection is trying to use TIMP1 as a using enzyme-linked immunosorbent assay (ELISA).
    [Show full text]
  • Demethylation of TIMP2 and TIMP3 Inhibit Cell Proliferation, Migration and Invasion in Pituitary Adenoma
    Demethylation of TIMP2 and TIMP3 inhibit cell proliferation, migration and invasion in pituitary adenoma Yongdong Yang the Second Aliated Hospital of Guilin Medical University Fanjun Huang the Second aliated Hospital of Guilin Medical University Xiufu Wu the Second aliated Hospital of Guilin Medical University Chunqin Huang the Second aliated Hospital of Guilin Medical University Shenyu Li ( [email protected] ) the second aliated hospital of guilin medical university Research article Keywords: Invasive pituitary adenoma, TIMPs, DNA methylation, 5-AzaC, GH3 Posted Date: October 29th, 2019 DOI: https://doi.org/10.21203/rs.2.15805/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/15 Abstract Background: Pituitary adenoma (PA) is one of the most common intracranial neoplasms. Tissue inhibitors of metalloproteinases (TIMPs) are prognostic biological markers, but their biological roles remains largely unclear in invasive PA. Methods: The promoter methylation status of TIMP2 and TIMP3 genes in invasive PA tissues and cells was measured by methylation-specic polymerase chain reaction (MSP). The expression of TIMP1-3 was validated by quantitative real time PCR and western blot analysis. Overexpression and knockdown of TIMP2 and TIMP3 in GH3 cells were created by transfection of pcDNA3.0 and siRNA against TIMP2 and TIMP3, respectively. Functional experiments in GH3 cells were performed with CCK-8 assay, wound healing assay and transwell assay. Effects of 5- Azacytidene (5-AzaC) on the methylation of TIMP2 and TIMP3 gene, and DNA methyltransferase 1 (DNMT1), DNMT3a and DNMT3b were determined by western blot analysis. Results: We found the expression of TIMP1, TIMP2 and TIMP3 was down-regulated in invasive PA tissues and cells.
    [Show full text]